Xtandi 40 MG capsule 120S
Ended Awarded Last action
- Contract number
- SPE2DR26FHNR4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,766
Award facts
- Contract value 100% obligated
- $12,766.02 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $12,766.02 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 40 mg capsules (120-count). This firm fixed-price delivery order, issued on December 3, 2025, with an ultimate completion date of December 4, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award represents performance under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for the Department of Defense's global pharmaceutical supply needs.
DMS Pharmaceutical Group holds a single-award IDC designated SPE2DR under the PPV-G GEN V program, awarded on November 13, 2025, with a $499,999,999 ceiling value and completion date of December 31, 2036. The contract encompasses a 30-month base period with three 30-month option periods and authorizes the Defense Logistics Agency to issue delivery orders for a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, vaccines, and medical consumables to support military healthcare facilities worldwide. The contractor's extensive product portfolio and demonstrated performance across multiple therapeutic categories position it as a critical supplier within the federal military medical supply chain.
Quick answers
Who was awarded contract SPE2DR26FHNR4?
SPE2DR26FHNR4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on December 3, 2025.
How much is contract SPE2DR26FHNR4 worth?
The government has obligated $12,766 on SPE2DR26FHNR4.
Is contract SPE2DR26FHNR4 an order under another contract?
Yes. SPE2DR26FHNR4 is a delivery order under SPE2DR25D9231, an indefinite delivery contract.
Was contract SPE2DR26FHNR4 competed?
The extent of competition for SPE2DR26FHNR4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award